PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32725927-10 2020 This phenotype could be partially rescued by treatment with the AngII type 1 receptor (AT1R) antagonist, losartan, suggesting that the observed effect was mediated by AngII acting on its main receptor. Losartan 105-113 angiotensin II, type I receptor-associated protein Mus musculus 64-85 32725927-10 2020 This phenotype could be partially rescued by treatment with the AngII type 1 receptor (AT1R) antagonist, losartan, suggesting that the observed effect was mediated by AngII acting on its main receptor. Losartan 105-113 angiotensin II, type I receptor-associated protein Mus musculus 87-91 32665776-10 2020 Our findings demonstrated that losartan ameliorates angiogenesis, inflammation and the induction of oxidative stress via Angiotensin II type I receptor (AT1R). Losartan 31-39 angiotensin II, type I receptor-associated protein Mus musculus 153-157 31886721-3 2020 We found that pretreatment with the AT1R blocker losartan inhibited the development of myogenic tone in these vessels but did not alter the luminal diameter of arterioles with preestablished tone. Losartan 49-57 angiotensin II, type I receptor-associated protein Mus musculus 36-40 30971441-0 2019 The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment. Losartan 33-41 angiotensin II, type I receptor-associated protein Mus musculus 88-92 30776402-8 2019 Intracerebroventricular infusion of selective AT1R antagonist, losartan, significantly attenuated freezing during CO2 inhalation, and during re-exposure to CO2 context, suggestive of AT1R modulation of contextual fear. Losartan 63-71 angiotensin II, type I receptor-associated protein Mus musculus 46-50 30776402-8 2019 Intracerebroventricular infusion of selective AT1R antagonist, losartan, significantly attenuated freezing during CO2 inhalation, and during re-exposure to CO2 context, suggestive of AT1R modulation of contextual fear. Losartan 63-71 angiotensin II, type I receptor-associated protein Mus musculus 183-187 31155290-10 2019 Furthermore, blocking the Ang II type 1 receptor (AT1R) with losartan effectively inhibited Ang II-induced macrophage apoptosis and AMPK/p38 MAPK/MCPIP1/ER pathway activation. Losartan 61-69 angiotensin II, type I receptor-associated protein Mus musculus 26-48 31155290-10 2019 Furthermore, blocking the Ang II type 1 receptor (AT1R) with losartan effectively inhibited Ang II-induced macrophage apoptosis and AMPK/p38 MAPK/MCPIP1/ER pathway activation. Losartan 61-69 angiotensin II, type I receptor-associated protein Mus musculus 50-54 30971441-4 2019 Losartan, a type I angiotensin II receptor (AT1R) antagonist, has been previously shown to have immunomodulatory actions involving monocyte and macrophage activity. Losartan 0-8 angiotensin II, type I receptor-associated protein Mus musculus 44-48 30971441-7 2019 We show, in this study, that losartan and its metabolite potently inhibit monocyte recruitment through the noncompetitive inhibition of CCL2-induced ERK1/2 activation, independent of AT1R activity. Losartan 29-37 angiotensin II, type I receptor-associated protein Mus musculus 183-187 30971441-9 2019 Collectively, these results indicate that losartan can exert antimetastatic activity by inhibiting CCR2 signaling and suppressing monocyte recruitment and therefore suggest that losartan (and potentially other AT1R blocker drugs) could be repurposed for use in cancer immunotherapy. Losartan 42-50 angiotensin II, type I receptor-associated protein Mus musculus 210-214 30061705-8 2018 The AT1R blocker, Losartan, normalized elevated blood pressure and markedly improved glomerular filtration in the shGRK2 knockdown mice. Losartan 18-26 angiotensin II, type I receptor-associated protein Mus musculus 4-8 30602301-1 2019 Objective- Pharmacological inhibition of the AT1R (angiotensin II type 1 receptor) with losartan can attenuate ascending aortic remodeling induced by transverse aortic constriction (TAC). Losartan 88-96 angiotensin II, type I receptor-associated protein Mus musculus 45-49 30602301-1 2019 Objective- Pharmacological inhibition of the AT1R (angiotensin II type 1 receptor) with losartan can attenuate ascending aortic remodeling induced by transverse aortic constriction (TAC). Losartan 88-96 angiotensin II, type I receptor-associated protein Mus musculus 51-81 29641288-5 2018 AngII type 1 receptor (AT1R) inhibitor losartan inhibited AngII-induced up-regulation of AGGF1, whereas AT2R inhibitor PD123319 further increased AngII-induced up-regulation of AGGF1. Losartan 39-47 angiotensin II, type I receptor-associated protein Mus musculus 0-21 29641288-5 2018 AngII type 1 receptor (AT1R) inhibitor losartan inhibited AngII-induced up-regulation of AGGF1, whereas AT2R inhibitor PD123319 further increased AngII-induced up-regulation of AGGF1. Losartan 39-47 angiotensin II, type I receptor-associated protein Mus musculus 23-27 29574718-8 2018 Inhibition of AT1 R with losartan in wild-type animals reproduces the effects of genetic ablation of AT1a R on ENaC activity arguing against contribution of developmental factors. Losartan 25-33 angiotensin II, type I receptor-associated protein Mus musculus 14-19 30030219-9 2018 In addition, the administration of an AT1R blocker, losartan, recovered the hypertensive phenotype of CTRP1 TG (transgenic) mice. Losartan 52-60 angiotensin II, type I receptor-associated protein Mus musculus 38-42 31535830-11 2019 Renal I/R increased cardiac levels of AT1R, which decreased after losartan or enalapril treatment. Losartan 66-74 angiotensin II, type I receptor-associated protein Mus musculus 38-42 28500295-5 2017 Interestingly, by protein-protein docking and molecular dynamics simulations, we described that a stable heterotetrameric interaction may exist between AT1R and A2AR bound to antagonists (i.e. losartan and istradefylline, respectively). Losartan 193-201 angiotensin II, type I receptor-associated protein Mus musculus 152-156 28976133-2 2017 The objective of this pilot study was to explore that potential role by determining whether the AT1R blocker, losartan, would reduce the growth of LAPC-4 prostate cancer xenografts in nude mice. Losartan 110-118 angiotensin II, type I receptor-associated protein Mus musculus 96-100 25902863-6 2016 In addition, the Ang II-induced autophagy and subsequent cell apoptosis could be fully abolished by an AT1R antagonist losartan rather than PD1223319, an antagonist for AT2R. Losartan 119-127 angiotensin II, type I receptor-associated protein Mus musculus 103-107 28034895-9 2017 Studies in control mice revealed that both P2X1R (MRS2159) and AT1R (losartan) antagonists significantly attenuated Up4A-induced aortic contraction. Losartan 69-77 angiotensin II, type I receptor-associated protein Mus musculus 63-67 28261571-7 2017 Both, AT1R-/- OT-I cells and WT OT-I cells from losartan- or captopril-treated mice showed lower expansion, reduced IL-2 production and IL-2Ralpha expression, lower activation (lower expression of CD69, CD44 and CD160) and lower exhaustion profiles. Losartan 48-56 angiotensin II, type I receptor-associated protein Mus musculus 6-10 26676112-0 2016 AT1R blocker losartan attenuates intestinal epithelial cell apoptosis in a mouse model of Crohn"s disease. Losartan 13-21 angiotensin II, type I receptor-associated protein Mus musculus 0-4 26676112-2 2016 The present study aimed to investigate the protective effects of the AT1R blocker losartan on 2,4,6-trinitrobenzenesulphonic acid (TNBS)-induced colitis. Losartan 82-90 angiotensin II, type I receptor-associated protein Mus musculus 69-73 26676112-9 2016 These results suggested that the AT1R blocker losartan may attenuate TNBS-induced colitis by inhibiting the apoptosis of IECs. Losartan 46-54 angiotensin II, type I receptor-associated protein Mus musculus 33-37 26133668-5 2016 Control and db/db mice were given AT1R blocker losartan via drinking water for 4 weeks. Losartan 47-55 angiotensin II, type I receptor-associated protein Mus musculus 34-38 26930476-4 2016 Notably, the AT1R antagonist losartan protected against the renal toxicity induced by cocaine, whereas the NFkappaB inhibitor pyrrolidine dithiocarbamate was not protective. Losartan 29-37 angiotensin II, type I receptor-associated protein Mus musculus 13-17 25556973-4 2015 The same effect was also observed after the addition of the AT1R antagonist losartan but not the AT2R inhibitor PD123,319. Losartan 76-84 angiotensin II, type I receptor-associated protein Mus musculus 60-64 26502868-3 2015 We tested whether losartan, a selective antagonist against type 1 angiotensin II receptors (AT1R) with noted antifibrotic activity, can enhance the penetration and efficacy of doxorubicin. Losartan 18-26 angiotensin II, type I receptor-associated protein Mus musculus 92-96 26241336-11 2015 Importantly, these effects were alleviated by 50 muM propofol, nNOS inhibitor S-methyl-l-thiocitrulline (SMTC) and angiotensin type 1 receptor (AT1R) blocker losartan, but not AT2R blocker PD123319. Losartan 158-166 angiotensin II, type I receptor-associated protein Mus musculus 115-142 26241336-11 2015 Importantly, these effects were alleviated by 50 muM propofol, nNOS inhibitor S-methyl-l-thiocitrulline (SMTC) and angiotensin type 1 receptor (AT1R) blocker losartan, but not AT2R blocker PD123319. Losartan 158-166 angiotensin II, type I receptor-associated protein Mus musculus 144-148 25994957-4 2015 Concurrently, mice were intracerebroventricularly infused with the AT1R blocker losartan, angiotensin-converting-enzyme inhibitor captopril, or artificial cerebrospinal fluid for 3 wk. Losartan 80-88 angiotensin II, type I receptor-associated protein Mus musculus 67-71 25994957-5 2015 Intracerebroventricular infusion of losartan or captopril attenuated DOCA-salt-induced PRR mRNA elevation in the paraventricular nucleus of the hypothalamus, suggesting a role for ANG II/AT1R signaling in regulating PRR expression during DOCA-salt hypertension. Losartan 36-44 angiotensin II, type I receptor-associated protein Mus musculus 187-191 25921929-5 2015 The autonomic dysregulation is prevented by treatment of young Sgcd-/- mice with the angiotensin II type 1 receptor blocker losartan. Losartan 124-132 angiotensin II, type I receptor-associated protein Mus musculus 85-115 25921929-12 2015 Treatment with the AT1 R blocker losartan for 7-9 weeks beginning at 3 weeks of age prevented or strongly attenuated the abnormalities in Sgcd-/- mice (P < 0.05). Losartan 33-41 angiotensin II, type I receptor-associated protein Mus musculus 19-24 25666589-6 2015 Furthermore, the Ang II-induced oxidative stress and subsequent apoptosis could be completely abolished by AT1R blocker losartan rather than AT2R blocker PD1223319, suggesting that the aforementioned detrimental effects of Ang II are mediated by AT1R. Losartan 120-128 angiotensin II, type I receptor-associated protein Mus musculus 107-111 26221650-8 2015 Moreover, treatment with an AT(1)R blocker, losartan, selectively reversed the signaling changes and ameliorated adverse phenotypic effects in the combination of aging and inflammation as well as each independently. Losartan 44-52 angiotensin II, type I receptor-associated protein Mus musculus 28-34 25666589-6 2015 Furthermore, the Ang II-induced oxidative stress and subsequent apoptosis could be completely abolished by AT1R blocker losartan rather than AT2R blocker PD1223319, suggesting that the aforementioned detrimental effects of Ang II are mediated by AT1R. Losartan 120-128 angiotensin II, type I receptor-associated protein Mus musculus 246-250 24760518-7 2014 Exogenous Ang II was degraded less efficiently by kidneys from ACE2KO mice than WT mice, and administration of an AT1R blocker (losartan 30 mg/kg/day) resulted in normalization of NADPH oxidase activity in the ACE2KO. Losartan 128-136 angiotensin II, type I receptor-associated protein Mus musculus 114-118 25485905-6 2015 The increase in endothelial reactive oxygen species in response to elevated PTM was reduced by the ANG II type 1 receptor (AT1R) antagonists losartan (3 muM) or valsartan (1 muM). Losartan 141-149 angiotensin II, type I receptor-associated protein Mus musculus 99-121 25485905-6 2015 The increase in endothelial reactive oxygen species in response to elevated PTM was reduced by the ANG II type 1 receptor (AT1R) antagonists losartan (3 muM) or valsartan (1 muM). Losartan 141-149 angiotensin II, type I receptor-associated protein Mus musculus 123-127 23283823-7 2014 The treatment with losartan further significantly increased the expression of AGT, renin, angiotensin II and AT1R, and reduced the expression of AT2R receptor as compared to those of diabetic mice. Losartan 19-27 angiotensin II, type I receptor-associated protein Mus musculus 109-113 24768585-7 2014 HIV/MTC also displayed enhanced phosphorylation of both mTOR and p70S6K; interestingly this effect of HIV was further enhanced by losartan (an AT1R blocker). Losartan 130-138 angiotensin II, type I receptor-associated protein Mus musculus 143-147 25511041-8 2014 Captopril, an ACE inhibitor, and losartan, an AT1R blocker, decreased expression of ACE and AT1R, but increased expression of ACE2 and angiotensin II type 2 receptor in LLC cells under hypoxia. Losartan 33-41 angiotensin II, type I receptor-associated protein Mus musculus 46-50 25511041-8 2014 Captopril, an ACE inhibitor, and losartan, an AT1R blocker, decreased expression of ACE and AT1R, but increased expression of ACE2 and angiotensin II type 2 receptor in LLC cells under hypoxia. Losartan 33-41 angiotensin II, type I receptor-associated protein Mus musculus 92-96 25225202-6 2014 These effects were prevented by both the Ang-II type 1 receptor (AT1R) blocker losartan and the lysosomal inhibitor leupeptin. Losartan 79-87 angiotensin II, type I receptor-associated protein Mus musculus 41-63 25225202-6 2014 These effects were prevented by both the Ang-II type 1 receptor (AT1R) blocker losartan and the lysosomal inhibitor leupeptin. Losartan 79-87 angiotensin II, type I receptor-associated protein Mus musculus 65-69 25413327-8 2014 Losartan reduced AT1R expression in daytime (1.18 +- 0.1 vs. 0.85 +- 0.1; P < 0.05) with a trend toward a reduction in the AT1R mRNA expression in the nighttime (1.2 +- 0.1 vs. 1.0 +- 0.1; P > 0.05) but failed to restore circadian variability. Losartan 0-8 angiotensin II, type I receptor-associated protein Mus musculus 17-21 25413327-8 2014 Losartan reduced AT1R expression in daytime (1.18 +- 0.1 vs. 0.85 +- 0.1; P < 0.05) with a trend toward a reduction in the AT1R mRNA expression in the nighttime (1.2 +- 0.1 vs. 1.0 +- 0.1; P > 0.05) but failed to restore circadian variability. Losartan 0-8 angiotensin II, type I receptor-associated protein Mus musculus 126-130 24088954-3 2014 Here we tested whether treatment of type 2 diabetic db/db mice with the AT1R blocker losartan not only ameliorates diabetic nephropathy, but also reverses epigenetic changes. Losartan 85-93 angiotensin II, type I receptor-associated protein Mus musculus 72-76 24424956-7 2014 Ang II treatment caused an increase in the size and weight of the tumor mass in nude mice, whereas the AT1R antagonist losartan significantly inhibited the size and weight of the tumor. Losartan 119-127 angiotensin II, type I receptor-associated protein Mus musculus 103-107 24420847-9 2014 This study provides in vivo evidence that losartan attenuates microvascular permeability via down-regulates Ang II and AT-1R expression in mechanical ventilator-induced lung injury in diabetic mice. Losartan 42-50 angiotensin II, type I receptor-associated protein Mus musculus 119-124 23515786-6 2013 Surprisingly, the AT1R immunoreactivity in the cerebellar cortex was remarkably reduced following 5 and 10 min of hypoxia or direct administration of an AT1R antagonist, losartan. Losartan 170-178 angiotensin II, type I receptor-associated protein Mus musculus 18-22 23981717-8 2013 The local Ang II receptor (AT1R) blocker losartan had negligible effect on tone or [Ca(2+)]i in control FAs, but reduced the basal tone by ~9% in Ang II FAs. Losartan 41-49 angiotensin II, type I receptor-associated protein Mus musculus 27-31 23515786-6 2013 Surprisingly, the AT1R immunoreactivity in the cerebellar cortex was remarkably reduced following 5 and 10 min of hypoxia or direct administration of an AT1R antagonist, losartan. Losartan 170-178 angiotensin II, type I receptor-associated protein Mus musculus 153-157 22465219-4 2012 We also examined if AT(2)R-mediated vasorelaxation is preserved after long-term treatment with the AT(1)R antagonist losartan. Losartan 117-125 angiotensin II, type I receptor-associated protein Mus musculus 99-105 23292716-7 2013 Prolonged pre- and postsurgical treatment of Cx40(-/-) mice with losartan (an AT1R antagonist) normalized blood pressure but did not improve tissue perfusion or survival, despite reduced macrophage infiltration. Losartan 65-73 angiotensin II, type I receptor-associated protein Mus musculus 78-82 22306536-7 2012 The AT1R blocker losartan attenuated these effects of Ang II. Losartan 17-25 angiotensin II, type I receptor-associated protein Mus musculus 4-8 22378773-5 2012 In the presence of the AT(1)R antagonist losartan, ANG II increased NO production in isolated mNTS neurons, an effect blocked by the AT(2)R antagonist PD123319, but not the angiotensin (1-7) antagonist D-Ala. Studies in mNTS neurons of nNOS-null or endothelial NOS (eNOS)-null mice established nNOS as the source of NO. Losartan 41-49 angiotensin II, type I receptor-associated protein Mus musculus 23-29 20136508-4 2010 Acute exposure to AT(1)R blocker losartan restored the impaired endothelium-dependent dilatations in aortas of db/db mice and also in renal arteries of diabetic patients (fasting plasma glucose level > or =7.0 mmol/l). Losartan 33-41 angiotensin II, type I receptor-associated protein Mus musculus 18-24 21870055-6 2011 A group of animals was treated with the AT1R blocker losartan. Losartan 53-61 angiotensin II, type I receptor-associated protein Mus musculus 40-44 21325494-8 2011 Pretreatment with the angiotensin AT(1) receptor (AT1R) antagonist losartan (3 x 10(-6) M) blocked ANG II (10(-9) M)-stimulated AQP2 protein expression and cAMP accumulation, and partially blocked dDAVP (10(-10) M)- and dDAVP+ANG II-induced AQP2 protein expression and cAMP accumulation. Losartan 67-75 angiotensin II, type I receptor-associated protein Mus musculus 34-48 21325494-8 2011 Pretreatment with the angiotensin AT(1) receptor (AT1R) antagonist losartan (3 x 10(-6) M) blocked ANG II (10(-9) M)-stimulated AQP2 protein expression and cAMP accumulation, and partially blocked dDAVP (10(-10) M)- and dDAVP+ANG II-induced AQP2 protein expression and cAMP accumulation. Losartan 67-75 angiotensin II, type I receptor-associated protein Mus musculus 50-54 20370487-4 2010 Here we treated the APP/PS1 transgenic mouse model of AD with the ARB losartan (10 mg/kg body weight) to determine whether blockade of the AT-II receptor subtype 1 (AT1-R) with intranasal losartan, using at a dosage far below its systemic antihypertensive dose, could maintain its neuroprotective effects independent of its systemic vasoactive action. Losartan 188-196 angiotensin II, type I receptor-associated protein Mus musculus 165-170 19604148-5 2009 These effects were abrogated by losartan, an AT-1R antagonist, but not by [Sar1,Thr8]-Ang II (Sar is sarcosine), an inactive analogue of Ang II, or by a neutralizing antibody against Ang I/II. Losartan 32-40 angiotensin II, type I receptor-associated protein Mus musculus 45-50 17508912-5 2007 Losartan, an AT1R antagonist, was given to 4-week-old obese db/db mice for a period of 8 weeks. Losartan 0-8 angiotensin II, type I receptor-associated protein Mus musculus 13-17 19540938-5 2009 Moreover, the production of IFN-gamma and TNF-alpha through CTL stimulation can be inhibited by the selective AT1R inhibitor, Losartan. Losartan 126-134 angiotensin II, type I receptor-associated protein Mus musculus 110-114 16469824-3 2006 The AT1-R-antagonist Losartan (Los) attenuates leukocyte recruitment following I/R. Losartan 21-29 angiotensin II, type I receptor-associated protein Mus musculus 4-9 17493931-4 2007 ANG II treatment induced an increase in collagen synthesis, which was abrogated by co-treatment with losartan (an AT-1R antagonist), wortmannin (a phosphoinositide 3-kinase (PI3K) inhibitor), an Akt inhibitor, and stable transfection of dominant negative-Akt1. Losartan 101-109 angiotensin II, type I receptor-associated protein Mus musculus 114-119 15655122-9 2005 The oxidative stress and AT1-R upregulation were reduced by losartan, but the P-selectin response was not. Losartan 60-68 angiotensin II, type I receptor-associated protein Mus musculus 25-30 16443769-4 2006 In addition, the AT1R antagonist losartan was administered orally to 4-week-old db/db mice for an 8-week period. Losartan 33-41 angiotensin II, type I receptor-associated protein Mus musculus 17-21 34171513-4 2021 Inhibition of TGF-beta signaling by blockage of the ang-II receptor 1 (AT1R) via losartan administration leads to improvement of cardiovascular and pulmonary phenotypes, but has no effect on skeletal phenotype in the haploinsufficient mouse model of MFS mgR, suggesting a distinct mechanism of pathogenesis in the skeletal system. Losartan 81-89 angiotensin II, type I receptor-associated protein Mus musculus 71-75 34761239-28 2021 However, more importantly, blocking the activation of AT1R with the angiotensin receptor blocker Losartan effectively abrogated AAA development. Losartan 97-105 angiotensin II, type I receptor-associated protein Mus musculus 54-58 34583123-3 2021 Meanwhile, Losartan, an angiotensin one receptor (AT1R) antagonist, attenuates the TH17-related responses. Losartan 11-19 angiotensin II, type I receptor-associated protein Mus musculus 50-54 34400742-8 2021 We also showed that treatment of bleomycin-induced vitamin D-deficient mice with AT1R antagonist losartan relieved weight loss, substantially ameliorated lung fibrosis and markedly blocked TGF-beta induction in the lung. Losartan 97-105 angiotensin II, type I receptor-associated protein Mus musculus 81-85 35486382-6 2022 Losartan treatment for four weeks is associated with lower AT1R protein level, Nitrotyrosine, and Tau protein in the frontal cortex of aged IL-10 -/- mice. Losartan 0-8 angiotensin II, type I receptor-associated protein Mus musculus 59-63 34107734-9 2021 Impaired endothelial responses were restored to normal by losartan, an AT1R (angiotensin II type 1 receptor) antagonist. Losartan 58-66 angiotensin II, type I receptor-associated protein Mus musculus 71-75 34107734-9 2021 Impaired endothelial responses were restored to normal by losartan, an AT1R (angiotensin II type 1 receptor) antagonist. Losartan 58-66 angiotensin II, type I receptor-associated protein Mus musculus 77-107 35486382-7 2022 Our results highlight the impact of Losartan, an AT1R blocker commonly prescribed for treating high blood pressure, on the brain-specific angiotensin system and AT1R-linked downstream effects such as brain oxidative stress damage and Tau burden in a frailty mouse model. Losartan 36-44 angiotensin II, type I receptor-associated protein Mus musculus 49-53 35486382-7 2022 Our results highlight the impact of Losartan, an AT1R blocker commonly prescribed for treating high blood pressure, on the brain-specific angiotensin system and AT1R-linked downstream effects such as brain oxidative stress damage and Tau burden in a frailty mouse model. Losartan 36-44 angiotensin II, type I receptor-associated protein Mus musculus 161-165 33380422-10 2021 Treatment with the AT1-R antagonist losartan inhibits lung tumor formation in K-RasLA2-G12D mice. Losartan 36-44 angiotensin II, type I receptor-associated protein Mus musculus 19-24 32969473-6 2020 Losartan, an antagonist of AT1R, reduced lymphoma volume and size in nude mice, and the proliferation and viability and the PCNA and Ki67 levels of SNK-6 cells. Losartan 0-8 angiotensin II, type I receptor-associated protein Mus musculus 27-31 33013481-8 2020 This effect was completely blocked by losartan, an angiotensin II type 1 receptor (AT1R) antagonist. Losartan 38-46 angiotensin II, type I receptor-associated protein Mus musculus 51-81 33013481-8 2020 This effect was completely blocked by losartan, an angiotensin II type 1 receptor (AT1R) antagonist. Losartan 38-46 angiotensin II, type I receptor-associated protein Mus musculus 83-87